Evaxion is disrupting the drug discovery process

We have developed two unique artificial intelligence platforms, PIONEER and EDEN that utilize and integrate the power of neural networks, big data, and supercomputing to identify the most suitable targets for immunotherapies targeting cancer and infectious diseases.

Evaxion is disrupting the drug discovery process

We have developed two unique artificial intelligence platforms, PIONEER and EDEN that utilize and integrate the power of neural networks, big data, and supercomputing to identify the most suitable targets for immunotherapies targeting cancer and infectious diseases.

PIONEER

PIONEER is Evaxion’s immuno-oncology platform focused on developing personalized cancer immunotherapies. It uses sophisticated algorithms to identify and select those neo-epitopes (tumor-specific mutations) that are most likely to generate a profound anti-cancer immune response. The newly identified neoepitopes are then applied in a therapeutic immunization strategy which delivers personalized, synthetic neoepitopes to patients.

Evaxion has improved the prediction power of PIONEER to supersede current, state-of-the-art technologies. PIONEER is utilized to build a unique pipeline of personalized cancer immunotherapies using different delivery modalities.

PIONEER is a fully automated platform that allows for rapid development of personalized immunotherapies for most types of cancer.

EDEN

EDEN has the ability to identify novel, bacterial vaccine antigens that trigger robust, protective immune responses against a broad range of bacterial sub-strains in a matter of hours.

Taking advantage of the rapid increase in big data from modern, high throughput sequencing studies, EDEN utilizes proteomes from clinically relevant pathogen strains as input. With specialized machine learning methods, EDEN targets immune evasion strategies of bacteria and outputs a list of proteins ranked by their capability to induce both a comprehensive and defensive immune response.

This groundbreaking technology can be applied in the discovery of novel vaccine antigens against multi-drug resistant bacteria at an unprecedented rate. 

© Copyright 2019 EVAXION BIOTECH A/S - All rights reserved